Ceapro Logo.jpg
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
28 mars 2024 07h55 HE | Ceapro Inc.
TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to...
Ceapro Logo.jpg
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
12 mars 2024 14h10 HE | Ceapro Inc.; Aeterna Zentaris Inc.
TORONTO and EDMONTON, Alberta, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to...
Ceapro Logo.jpg
Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
26 févr. 2024 07h30 HE | Ceapro Inc.
ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and...
Ceapro Logo.jpg
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
23 févr. 2024 09h00 HE | Ceapro Inc.
EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business. On...
Ceapro Logo.jpg
Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris
15 févr. 2024 17h50 HE | Ceapro Inc.
EDMONTON, Alberta, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro” or the “Company”) is pleased to announce that it has mailed and filed a management information...
Ceapro Logo.jpg
Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
13 déc. 2023 08h46 HE | Ceapro Inc.
– Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute – No adverse reactions observed, and study can continue as planned EDMONTON, Alberta, Dec. 13, 2023 (GLOBE NEWSWIRE) --...
Ceapro Logo.jpg
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
29 nov. 2023 09h05 HE | Ceapro Inc.
– Product development focused on the production of powder formulations of oat beta glucan and avenanthramides for cosmeceuticals market – Technology development focused on the PGX pilot scale...
Ceapro Logo.jpg
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
27 nov. 2023 09h15 HE | Ceapro Inc.
Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute Screening of healthy subjects is now underway Phase 1-2a study to provide valuable insights into the safety and...
Ceapro Logo.jpg
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
07 nov. 2023 08h05 HE | Ceapro Inc.
PGX processing unit with a 10X (100 L) vessel capacity to be installed and tested at NATEX pilot testing facility in AustriaYeast beta glucan (YBG) to be the first bio active to be processed at this...
Ceapro Logo.jpg
Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update
29 août 2023 09h05 HE | Ceapro Inc.
- $5.5 million first six-month 2023 sales vs. $11.7 million for the same period in 2022; sales lagging by one quarter due to stocking campaign by one major customer in 2022 and further Marketplace...